Pharmaceuticals

Drug Development Biotechnology Drug Pricing Acquisitions Manufacturing Drug Manufacturing Vaccine Development Mergers and Acquisitions Corporate Governance Market Competition

Pfizer Licenses Early-Stage Oral GLP-1 From YaoPharma in Up to $2 Billion Deal

The deal brings an oral obesity candidate into Pfizer’s pipeline, with YaoPharma finishing Phase 1 in Australia before a planned handoff.

Eli Lilly Picks Huntsville for $6 Billion API Plant to Scale Obesity Pill Production

Telix Class Action Seeks Losses After SEC Subpoena and FDA CRL Disclosures

Kymera Jumps on KT-621 Phase 1b Win, Advancing Oral STAT6 Degrader Into Phase 2b

FDA Qualifies First AI Tool for MASH Drug Trials

Mirum to Acquire Bluejay Therapeutics in Up to $820 Million Deal for Hepatitis D Drug

Dyne’s DMD Drug Hits Primary Endpoint in DELIVER REC, Shows Functional Gains

Recalls Expand for Abbott FreeStyle Libre 3 Sensors Over False Low Readings

Okava Launches First GLP-1 Implant Trial for Overweight Cats

FDA Meeting Minutes Undercut uniQure’s Plan to File Huntington’s Gene Therapy for Approval

FDA Grants Biologic Approval to Axogen’s Avance Nerve Graft for Peripheral Nerve Repair

Bristol Myers Delays ADEPT-2 Alzheimer’s Psychosis Readout to 2026 After Site Irregularities

Telix Securities Suit Advances as Investor Firms Push Lead-Plaintiff Bids Before Jan. 9 Deadline

Lilly Cuts Zepbound Cash Prices on LillyDirect as GLP‑1 Price Competition Deepens

Vaccine Stocks Slide After FDA Memo Alleging Child Deaths and Tougher Approval Standards

Regeneron, Tessera Strike $150 Million Gene-Editing Pact for Alpha‑1 Antitrypsin Deficiency

Telix Faces Securities Class Action Over Prostate Cancer Disclosures and Supply Chain Claims

Jennifer Lopez Delivers Full Set at Lavish Udaipur Wedding

Telix Hit With Securities Class Action Over Prostate-Drug Claims and Supply Chain Assurances

FDA Approves Durvalumab Added to Perioperative FLOT for Resectable Gastric and GEJ Cancer